Eli Lilly and Bristol-Myers Squibb announced that they have stopped enrollment in one of their two global Phase 3 studies evaluating necitumumab as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.